239 filings
Page 7 of 12
8-K
4j1wd35jynstc72y0q2m
29 May 18
Departure of Directors or Certain Officers
4:20pm
8-K
wgr30m8r7 n9ewh
23 May 18
Departure of Directors or Certain Officers
4:16pm
8-K
qd915buik
8 May 18
Kadmon Provides Business Update and Reports First Quarter 2018 Financial Results
4:26pm
8-K
cucqyhsfecca 8ro
10 Apr 18
Kadmon Receives FDA Guidance on Pivotal Clinical Trial Design for KD025 in Chronic Graft-Versus-Host Disease
12:00am
8-K
60ha8zp
9 Apr 18
Departure of Directors or Certain Officers
12:00am
8-K
ms5us6pd0yw
6 Mar 18
Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2017 Financial Results
12:00am
8-K
9wad6pg 5e
23 Feb 18
Kadmon Announces Updated Positive Results from Phase 2 Study of KD025 in cGVHD
12:00am
8-K
f3dpc b4u3t3ce1kzla9
12 Feb 18
Kadmon Announces Positive Topline Results from Phase 2 Study of KD025
12:00am
424B5
cs6wzr11 lkyal
12 Jan 18
Prospectus supplement for primary offering
12:00am
424B5
ucxotc5a
12 Jan 18
Prospectus supplement for primary offering
12:00am
EFFECT
wgptk4rh
10 Jan 18
Notice of effectiveness
12:00am
UPLOAD
kvuqkzllmxb59055to1
10 Jan 18
Letter from SEC
12:00am
CORRESP
xfo9te2lset24j5807dk
8 Jan 18
Correspondence with SEC
12:00am
8-K
btfs614rqag
26 Dec 17
Other Events
12:00am
8-K
6yqqb17 2njea
11 Dec 17
Regulation FD Disclosure
12:00am
8-K
e1zgowsqr2mmcwj
11 Dec 17
Kadmon Presents Updated Positive Phase 2 Data on KD025 in cGVHD at ASH Annual Meeting
12:00am
8-K
ri6qjdd39d7s
13 Nov 17
Other Events
12:00am